Evidence map›Paper›PMID 27090218›Full record

Trial reportLipids in health and disease2016

Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial.

Mariona Balfegó, Silvia Canivell, Felicia A Hanzu, Aleix Sala-Vila, Margarita Martínez-Medina, Serafín Murillo, Teresa Mur, Elena G Ruano, Francisca Linares, Nuria Porras and 10 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02294526 (PILCHARDUS STUDY), which is not on this map. Cited by 73 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 9 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02294526 nacompletednot on this map

PILCHARDUS STUDY: A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients

TypeinterventionalSponsorSpanish Biomedical Research Centre in Diabetes and Associated Metabolic DisordersRan2012 to 2013Enrolled35ConditionsType 2 DiabetesArmsSardine diet
3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 9 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Systematic Review of the Effect of Enteral Feeding on Gut Microbiota in Preterm Infants.Journal of obstetric, gynecologic, and neonatal nursing : JOGNN · 2018
    Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 2 countries.

Mariona BalfegóCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain. mbalfego@clinic.ub.es.
Silvia CanivellDiabetes and Obesity Research Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), c/ Roselló 149 planta 5, 08036, Barcelona, Spain.
Felicia A HanzuCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Aleix Sala-VilaCIBER in Physiopathology of Obesity and Nutrition (CIBERobn), c/Villarroel 170, Edifici Helios, 08036, Barcelona, Spain.
Margarita Martínez-MedinaLaboratory of Molecular Microbiology, Biology Department, University of Girona, Av. Montilivi s/n, E-17071, Girona, Spain.
Serafín MurilloCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Teresa MurTerrassa Sud Primary Health Care Center, Mútua de Terrassa, Av. Santa Eulàlia s/n, 08223, Terrassa, Barcelona, Spain.
Elena G RuanoCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Francisca LinaresCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Nuria PorrasCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Silvia ValladaresCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Maria FontalbaCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Elena RouraAlicia Foundation, Camí Sant Benet, 08272 Sant Fruitós de Bages, Barcelona, Spain.
Anna NovialsCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Cristina HernándezCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Gloria ArandaDepartment of Endocrinology and Nutrition, Hospital Clínic of Barcelona, c/Villarroel 170 Escala 11 planta 2, 08036, Barcelona, Spain.
Antoni Sisó-AlmirallLes Corts Primary Health Care Center, Tranverse Group for Research in Primary Care, IDIBAPS, c/ Mejia Lequerica s/n, 08028, Barcelona, Spain.
Gemma Rojo-MartínezCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Rafael SimóCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Ramon GomisCIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESHospital Clínic de Barcelona · ESInstituto de Investigación Biomédica de Málaga · ESUniversitat de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ESUniversity Hospital Mútua de Terrassa · ESUniversity Hospital of Lausanne · CHUniversity of Girona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion of fish (particularly oily fish) at least two times per week is recommended by current international dietary guidelines for type 2 diabetes. In contrast to a large number of human studies examining the effects of oily fish on different cardiovascular risk factors, little research on this topic is available in patients with type 2 diabetes. The aims of this pilot study were to investigate the effects of a sardine-enriched diet on metabolic control, adiponectin, inflammatory markers, erythrocyte membrane fatty acid (EMFA) composition, and gut microbiota in drug-naïve patients with type 2 diabetes.

methods35 drug-naïve patients with type 2 diabetes were randomized to follow either a type 2 diabetes standard diet (control group: CG), or a standard diet enriched with 100 g of sardines 5 days a week (sardine group: SG) for 6 months. Anthropometric, dietary information, fasting glycated hemoglobin, glucose, insulin, adiponectin, inflammatory markers, EMFA and specific bacterial strains were determined before and after intervention.

resultsThere were no significant differences in glycemic control between groups at the end of the study. Both groups decreased plasma insulin (SG: -35.3%, P = 0.01, CG: -22.6%, P = 0.02) and homeostasis model of assessment--insulin resistance (HOMA-IR) (SG: -39.2%, P = 0.007, CG: -21.8%, P = 0.04) at 6-months from baseline. However only SG increased adiponectin in plasma compared to baseline level (+40.7%, P = 0.04). The omega-3 index increased 2.6% in the SG compared to 0.6% in the CG (P = 0.001). Both dietary interventions decreased phylum Firmicutes (SG and CG: P = 0.04) and increased E. coli concentrations (SG: P = 0.01, CG: P = 0.03) at the end of the study from baseline, whereas SG decreased Firmicutes/Bacteroidetes ratio (P = 0.04) and increased Bacteroides-Prevotella (P = 0.004) compared to baseline.

conclusionsAlthough enriching diet with 100 g of sardines 5 days a week during 6 months to a type 2 diabetes standard diet seems to have neutral effects on glycemic control in drug-naïve patients with type 2 diabetes, this nutritional intervention could have beneficial effects on cardiovascular risk. Furthermore, both dietary interventions decreased HOMA-IR and altered gut microbiota composition of drug-naïve patients with type 2 diabetes.

trial registrationTrial number and name of the registry: NCT02294526, ClinicalTrials.gov.

Indexed as

FishesGastrointestinal MicrobiomeAdiponectinAnimalsBiomarkersBody CompositionDiabetes Mellitus, Type 2Erythrocyte MembraneFatty AcidsFatty Acids, Omega-3FemaleFish ProductsHumansInflammationMaleMiddle AgedAdiponectinADIPOQ protein, humanBiomarkersFatty AcidsFatty Acids, Omega-3Nutrition therapyOily fishPilot trialSardineType 2 diabetes

Identifiers

PMID27090218
PMCPMC4836051
OpenAlexW2337509055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.